Nonhuman primate models for evaluation of SARS-CoV-2 vaccines

References

• Gartner MJ, Subbarao K. The threat of zoonotic coronaviruses. Microbiol Aust. 2021;42(1):4–9.
   Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in china, 2019. N Engl J Med. 2020;382(8):727–733. DOI:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544.
   PubMed Web of Science ®Google Scholar
• Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021;12(1). DOI:10.1128/mBio.03647-20.
   Web of Science ®Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829. DOI:10.1016/S0140-6736(21)00947-8.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the pfizer-biontech and oxford-astrazeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373(1088). DOI:10.1136/bmj.n1088.
   PubMedGoogle Scholar
• Christie A, Henley SJ, Mattocks L, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 Vaccine - United States. September 6, 2020 May 1,2021. MMWR Morb Mortal Wkly Rep, 70(23), 858–864 ( 2021 10.15585/mmwr.mm7023e2
   Web of Science ®Google Scholar
• Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–1973.
   PubMed Web of Science ®Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945–946.
   PubMed Web of Science ®Google Scholar
• Li YD, Chi WY, Su JH, et al. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):104.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao S, Ou J, et al. COVID-19: coronavirus vaccine development updates. Front Immunol. 2020;11:602256.
   PubMed Web of Science ®Google Scholar
• Chatterjee R, Ghosh M, Sahoo S, et al. Next-Generation bioinformatics approaches and resources for coronavirus vaccine discovery and development-a perspective review. Vaccines (Basel). 2021;9(8):812. DOI:10.3390/vaccines9080812.
   PubMed Web of Science ®Google Scholar
• Mahapatra SR, Sahoo S, Dehury B, et al. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection. Expert Rev Vaccines. 2020;19(9):871–885. DOI:10.1080/14760584.2020.1811091.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970–4975. DOI:10.1073/pnas.1323279111.
   PubMed Web of Science ®Google Scholar
• McCray PB Jr., Pewe L, Wohlford-Lenane C, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813–821. DOI:10.1128/JVI.02012-06.
   PubMed Web of Science ®Google Scholar
• Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2021;19(3):211–219.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Hewitt JA, Lutz C, Florence WC, et al. ACTIVating resources for the COVID-19 pandemic: in vivo models for vaccines and therapeutics. Cell Host Microbe. 2020;28(5):646–659. DOI:10.1016/j.chom.2020.09.016.
   PubMed Web of Science ®Google Scholar
• Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (covid-19) in a golden syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis. 2020;71(9):2428–2446. DOI:10.1093/cid/ciaa644.
   PubMed Web of Science ®Google Scholar
• Kim YI, Kim SG, Kim SM, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 2020;27(5):704–709 e702. DOI:10.1016/j.chom.2020.03.023.
   PubMed Web of Science ®Google Scholar
• Sun J, Zhuang Z, Zheng J, et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell. 2020;182(3):734–743 e735. DOI:10.1016/j.cell.2020.06.010.
   PubMed Web of Science ®Google Scholar
• SR L, KH D, Schafer A, et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell. 2020;183(4):1070–1085 e1012. 3rd. DOI:10.1016/j.cell.2020.09.050.
   PubMed Web of Science ®Google Scholar
• Pymm P, Adair A, Chan LJ, et al. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021;118(19). DOI:10.1073/pnas.2101918118.
   PubMed Web of Science ®Google Scholar
• Singh DK, Singh B, Ganatra SR, et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets. Nat Microbiol. 2021;6(1):73–86. DOI:10.1038/s41564-020-00841-4.
   PubMed Web of Science ®Google Scholar
• Salguero FJ, White AD, Slack GS, et al. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat Commun. 2021;12(1):1260. DOI:10.1038/s41467-021-21389-9.
   PubMed Web of Science ®Google Scholar
• Woolsey C, Borisevich V, Prasad AN, et al. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol. 2021;22(1):86–98. DOI:10.1038/s41590-020-00835-8.
   PubMed Web of Science ®Google Scholar
• Lu S, Zhao Y, Yu W, et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther. 2020;5(1):157. DOI:10.1038/s41392-020-00269-6.
   PubMed Web of Science ®Google Scholar
• Munster VJ, Feldmann F, Williamson BN, et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature. 2020;585(7824):268–272. DOI:10.1038/s41586-020-2324-7.
   PubMed Web of Science ®Google Scholar
• Rockx B, Kuiken T, Herfst S, et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science. 2020;368(6494):1012–1015. DOI:10.1126/science.abb7314.
   PubMed Web of Science ®Google Scholar
• Smits SL, de Lang A, van den Brand Jm, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog. 2010;6(2):e1000756. DOI:10.1371/journal.ppat.1000756.
   PubMed Web of Science ®Google Scholar
• Blair RV, Vaccari M, Doyle-Meyers LA, et al. Acute respiratory distress in aged, SARS-CoV-2-Infected African Green Monkeys but Not Rhesus Macaques. Am J Pathol. 2021;191(2):274–282. DOI:10.1016/j.ajpath.2020.10.016.
   PubMed Web of Science ®Google Scholar
• KH D, SR L, Schafer A, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586(7830):560–566. 3rd. DOI:10.1038/s41586-020-2708-8.
   PubMed Web of Science ®Google Scholar
• Kim Y-I, Yu K-M, Koh J-Y, et al. Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets. Res Sq. 2021. DOI:10.21203/rs.3.rs-131380/v2.
   Google Scholar
• McAuliffe J, Vogel L, Roberts A, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology. 2004;330(1):8–15. DOI:10.1016/j.virol.2004.09.030.
   PubMed Web of Science ®Google Scholar
• Lawler JV, Endy TP, Hensley LE, et al. Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med. 2006;3(5):e149. DOI:10.1371/journal.pmed.0030149.
   PubMed Web of Science ®Google Scholar
• Rowe T, Gao G, Hogan RJ, et al. Macaque model for severe acute respiratory syndrome. J Virol. 2004;78(20):11401–11404. DOI:10.1128/JVI.78.20.11401-11404.2004.
   PubMed Web of Science ®Google Scholar
• Nasreen S, Chung H, He S et al, Effectiveness of mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. medRxiv. 2021:21259420 DOI:10.1101/2021.06.28.21259420.
   Google Scholar
• Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020;383(16):1544–1555. DOI:10.1056/NEJMoa2024671.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586(7830):567–571. DOI:10.1038/s41586-020-2622-0.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427–2438. DOI:10.1056/NEJMoa2028436.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920–1931. DOI:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. DOI:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. Clin Infect Dis. 2022;74(9): 1515–1524.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614–1621. DOI:10.1038/s41591-021-01446-y.
   PubMed Web of Science ®Google Scholar
• Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27:2136–2143.
   PubMed Web of Science ®Google Scholar
• Pajon R, Doria-Rose NA, Shen X, et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022;386(11):1088–1091. DOI:10.1056/NEJMc2119912.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Nason MC, Flach B, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science. 2021;373(6561):eabj0299. DOI:10.1126/science.abj0299.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Gagne M, Wagner DA, et al. Protection against SARS-CoV-2 beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Science. 2021;374(6573):1343–1353.
   PubMed Web of Science ®Google Scholar
• Gagne M, Moliva JI, Foulds KE et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron. bioRxiv. 2022:2002.2003.479037 DOI:10.1101/2022.02.03.479037.
   Google Scholar
• Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–289. DOI:10.1038/s41586-021-03275-y.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. DOI:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423. DOI:10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187–189. DOI:10.1056/NEJMc2104974.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021;385(7):585–594. DOI:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022;386:1532–1546.
   PubMed Web of Science ®Google Scholar
• Edara M VV, KE EM, et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep Med. 2022;3(2):100529. DOI:10.1016/j.xcrm.2022.100529
   Google Scholar
• Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022;28(3):477–480. DOI:10.1038/s41591-021-01676-0.
   PubMed Web of Science ®Google Scholar
• Chandrashekar A, Yu J, McMahan K, et al. Vaccine protection against the SARS-CoV-2 Omicron Variant in Macaques. bioRxiv. 2022. DOI:10.1101/2022.02.06.479285.
   PubMedGoogle Scholar
• Patel A, Walters J, Reuschel EL, et al. Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. bioRxiv. 2020:2007.2028.225649 DOI:10.1101/2020.07.28.225649.
   Google Scholar
• Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601. DOI:10.1038/s41467-020-16505-0.
   PubMed Web of Science ®Google Scholar
• Tebas P, Yang S, Boyer JD, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine. 2021;31:100689.
   PubMedGoogle Scholar
• Andrade VM, Christensen-Quick A, Agnes J, et al. INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. NPJ Vaccines. 2021;6(1):121. DOI:10.1038/s41541-021-00384-7.
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578–582. DOI:10.1038/s41586-020-2608-y.
   PubMed Web of Science ®Google Scholar
• Graham SP, McLean RK, Spencer AJ, et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines. 2020;5:69.
   PubMed Web of Science ®Google Scholar
• Barrett JR, Belij-Rammerstorfer S, Dold C, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(2):279–288. DOI:10.1038/s41591-020-01179-4.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270–278. DOI:10.1038/s41591-020-01194-5.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979–1993. DOI:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. DOI:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021;385:2348–2360.
   PubMed Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–588. DOI:10.1038/s41586-020-2607-z.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 Vaccine. N Engl J Med. 2021;384:1824–1835.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. DOI:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Polinski JM, Weckstein AR, Batech M, et al. Effectiveness of the single-dose Ad26.COV2.S COVID Vaccine. medRxiv. 2021:2009.2010.21263385 DOI:10.1101/2021.09.10.21263385.
   Google Scholar
• Guebre-Xabier M, Patel N, Tian JH, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38(50):7892–7896. DOI:10.1016/j.vaccine.2020.10.064.
   PubMed Web of Science ®Google Scholar
• Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 2016;34(16):1927–1935. DOI:10.1016/j.vaccine.2016.02.033.
   PubMed Web of Science ®Google Scholar
• Magnusson SE, Altenburg AF, Bengtsson KL, et al. Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice. Immunol Res. 2018;66(2):224–233. DOI:10.1007/s12026-018-8991-x.
   PubMed Web of Science ®Google Scholar
• Shinde V, Cho I, Plested JS, et al. Comparison of the safety and immunogenicity of a novel matrix-m-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a randomized controlled trial. medRxiv. 2022;22 (1):73–84.
   Google Scholar
• Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372. DOI:10.1038/s41467-020-20653-8.
   PubMed Web of Science ®Google Scholar
• Gorman MJ, Patel N, Guebre-Xabier M, et al. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination. bioRxiv. 2021:2002.2005.429759 DOI:10.1101/2021.02.05.429759.
   Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320–2332. DOI:10.1056/NEJMoa2026920.
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. N Engl J Med. 2021;385(13):1172–1183. DOI:10.1056/NEJMoa2107659.
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):531–543. DOI:10.1056/NEJMoa2116185.
   PubMed Web of Science ®Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1899–1909. DOI:10.1056/NEJMoa2103055.
   PubMed Web of Science ®Google Scholar
• Liang JG, Su D, Song TZ, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12(1):1346. DOI:10.1038/s41467-021-21634-1.
   PubMed Web of Science ®Google Scholar
• Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682–694. DOI:10.1016/S0140-6736(21)00241-5.
   PubMed Web of Science ®Google Scholar
• Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):461–472. DOI:10.1016/S0140-6736(22)00055-1.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81. DOI:10.1126/science.abc1932.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192. DOI:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222. DOI:10.1016/S0140-6736(21)01429-X.
   PubMed Web of Science ®Google Scholar
• Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385(10):875–884. DOI:10.1056/NEJMoa2107715.
   PubMed Web of Science ®Google Scholar
• Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486–489. DOI:10.1038/s41591-022-01704-7.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, et al. Development of an Inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–721 e719. DOI:10.1016/j.cell.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51.
   PubMed Web of Science ®Google Scholar
• Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: a Randomized Clinical Trial. JAMA. 2021;326(1):35–45. DOI:10.1001/jama.2021.8565.
   PubMed Web of Science ®Google Scholar
• Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 2021;10(1):1751–1759. DOI:10.1080/22221751.2021.1969291.
   PubMed Web of Science ®Google Scholar
• Yadav PD, Ella R, Kumar S, et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun. 2021;12(1):1386. DOI:10.1038/s41467-021-21639-w.
   PubMed Web of Science ®Google Scholar
• Mohandas S, Yadav PD, Shete-Aich A, et al. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model. iScience. 2021;24(2):102054. DOI:10.1016/j.isci.2021.102054.
   PubMed Web of Science ®Google Scholar
• Ganneru B, Jogdand H, Daram VK, et al. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation. iScience. 2021;24(4):102298. DOI:10.1016/j.isci.2021.102298.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950–961. DOI:10.1016/S1473-3099(21)00070-0.
   PubMed Web of Science ®Google Scholar
• Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637–646. DOI:10.1016/S1473-3099(20)30942-7.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. Lancet. 2021;398(10317) :2173–2184.
   PubMed Web of Science ®Google Scholar
• Yadav PD, Sapkal GN, Ella R, et al. Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med. 2021;28(7). DOI:10.1093/jtm/taab104.
   Web of Science ®Google Scholar
• Sapkal GN, Yadav PD, Ella R, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J Travel Med. 2021;28(4). DOI:10.1093/jtm/taab051.
   Web of Science ®Google Scholar
• Sapkal G, Yadav PD, Ella R, et al. Neutralization of VUI B.1.1.28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. J Travel Med. 2021;28(7). DOI:10.1093/jtm/taab077.
   Web of Science ®Google Scholar
• Desai D, Khan AR, Soneja M, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet Infect Dis. 2022;22(3):349–356. DOI:10.1016/S1473-3099(21)00674-5.
   PubMed Web of Science ®Google Scholar
• Liang Z, Zhu H, Wang X, et al. Adjuvants for Coronavirus Vaccines. Front Immunol. 2020;11:589833.
   PubMed Web of Science ®Google Scholar
• Gupta T, Gupta SK. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int Immunopharmacol. 2020;86:106717.
   PubMed Web of Science ®Google Scholar
• Simone A, Herald J, Chen A, et al. Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older. JAMA Intern Med. 2021;181:1668.
   PubMed Web of Science ®Google Scholar
• Pottegard A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with oxford-astrazeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373(1114). DOI:10.1136/bmj.n1114.
   PubMedGoogle Scholar
• Alghamdi AN, Alotaibi MI, Alqahtani AS, et al. BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among saudi vaccinees. Front Med (Lausanne). 2021;8:760047.
   PubMed Web of Science ®Google Scholar
• Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185–1191.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4). DOI:10.1172/jci.insight.123158.
   Web of Science ®Google Scholar
• Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–447.
   PubMed Web of Science ®Google Scholar
• Lu P, Guerin DJ, Lin S, et al. Immunoprofiling correlates of protection against shiv infection in adjuvanted HIV-1 pox-protein vaccinated rhesus macaques. Front Immunol. 2021;12:625030.
   PubMed Web of Science ®Google Scholar
• Dhakal S, Ruiz-Bedoya CA, Zhou R, et al. Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden syrian hamster model. mBio. 2021;12(4):e0097421. DOI:10.1128/mBio.00974-21.
   PubMed Web of Science ®Google Scholar
• Brady E, Nielsen MW, Andersen JP, et al. Lack of consideration of sex and gender in COVID-19 clinical studies. Nat Commun. 2021;12(1):4015.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588(7837):315–320. DOI:10.1038/s41586-020-2700-3.
   PubMed Web of Science ®Google Scholar
• Bignucolo A, Scarabel L, Mezzalira S, et al. Sex disparities in efficacy in COVID-19 Vaccines: a systematic review and meta-analysis. Vaccines (Basel). 2021;9(8). DOI:10.3390/vaccines9080825
   PubMed Web of Science ®Google Scholar
• Romero Starke K, Reissig D, Petereit-Haack G, et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6(12):e006434.
   PubMed Web of Science ®Google Scholar
• Kim YI, Yu KM, Koh JY, et al. Age-dependent pathogenic characteristics of SARS-CoV-2 infection in ferrets. Nat Commun. 2022;13(1):21. DOI:10.1038/s41467-021-27717-3.
   PubMedGoogle Scholar
• Bajaj V, Gadi N, Spihlman AP, et al. Immunity, and COVID-19: how age influences the host immune response to coronavirus infections? Front Physiol. 2020;11:571416.
   PubMed Web of Science ®Google Scholar
• Clay CC, Donart N, Fomukong N, et al. Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses. Immun Ageing. 2014;11(1):4. DOI:10.1186/1742-4933-11-4.
   PubMed Web of Science ®Google Scholar
• Mattison JA, Vaughan KL. An overview of nonhuman primates in aging research. Exp Gerontol. 2017;94:41–45.
   PubMed Web of Science ®Google Scholar
• Solforosi L, Kuipers H, Jongeneelen M, et al. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP. J Exp Med. 2021;218(7). DOI:10.1084/jem.20202756.
   PubMed Web of Science ®Google Scholar
• Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596(7872):417–422. DOI:10.1038/s41586-021-03739-1.
   PubMed Web of Science ®Google Scholar
• Maraskovsky E, Rockman S, Dyson A, et al. Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 southern hemisphere trivalent influenza vaccine. Vaccine. 2012;30(51):7400–7406. DOI:10.1016/j.vaccine.2012.09.083.
   PubMed Web of Science ®Google Scholar
• Turner JS, Kim W, Kalaidina E, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021;595:421–425.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, et al. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv. 2020:2009.2008.280818 DOI:10.1101/2020.09.08.280818.
   PubMedGoogle Scholar
• Tostanoski LH, Wegmann F, Martinot AJ, et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med. 2020;26(11):1694–1700. DOI:10.1038/s41591-020-1070-6.
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583(7818):834–838. DOI:10.1038/s41586-020-2342-5.
   PubMed Web of Science ®Google Scholar
• Meyer M, Wang Y. mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge. bioRxiv. 2021. DOI:10.1101/2021.01.25.428136
   Google Scholar
• Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat Commun. 2020;11(1):6059.
   PubMed Web of Science ®Google Scholar